Navamedic Asa · OSL:NAVA
Navamedic Asa — Q2 2024 Earnings Presentation
24 slides from Navamedic Asa's earnings presentation, Aug 16, 2024
Slide 1: Q2 and H1 2024 Highlights and key figures
Q2 and H1 2024 Highlights and key figures 16 August 2024 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Our edge explained
Our edge explained A reliable supplier of high-quality pharma products, within Prescription drugs (RX), Consumer Health, and Hospital products including Medical nutrition Presence and sales Strong local insight and across the Nordics understanding of patients’ needs Ambitious growth strategy With a
Slide 3: Key financial indicators | Second quarter and first half of 2024
Key financial indicators | Second quarter and first half of 2024 Stable growth continues and is supported by a new licensing and supply agreement Signed a license and supply agreement for Flexilev® and OraFID® with Orion REVENUE1 GROSS MARGIN1 Adjusted EBITDA1 Corporation Q2 Revenues in Q2 have had
Slide 4: The longer perspective
The longer perspective Growth on a scalable platform and through M&A +20% 500 Revenue growth and EBITDA 400 100 fluctuations from quarter to quarter mainly due to NOK million NOK million 300 seasonality and stock build- up/down effects 200 50 Milestone revenues from Orion agreement main reason for s
Slide 5: Commercialisation strategy for Flexilev: Europe
Commercialisation strategy for Flexilev® Commercialisation in Europe • License & Supply Agreement with Orion Corporation (Orion). • Orion has paved the way for Parkinson’s disease treatment in Europe, making them a strong commercial partner • The right to market and sell Flexilev in the OraFID conta
Slide 6: Commercialisation strategy for Flexilev: outside Europe
Commercialisation strategy for Flexilev® Commercialization outside Europe • Licensing outside Europe will be for Flexilev in the OraFID packaging (like Orion) • Navamedic is currently exploring regulatory requirements and market access opportunities for such a drug/device combination product in the
Slide 7: High-quality portfolio with several hero products
High-quality portfolio with several hero products Prescription Drugs (RX) Consumer Health Hospital Sold through pharmacies Sold through pharmacies Tenders incl. medical nutrition* YTD 2024 YTD 2024 57.7 revenue in revenue in 15% +14% 128.4 YTD 2024 MNOK -5.4% MNOK 68.3 revenue in MNOK YoY growth YoY
Slide 8: Prescription Drugs (RX)
Prescription Drugs (RX) Stable demand for key products The RX segment comprises Navamedic’s prescription products Q2 2024 revenue 70.1 MNOK 4% YOY GROWTH IN MYSIMBA® WHOLESALER (Q2 2023: 66.8 MNOK) VOLUME Vol. (units 000) 200 Q2 highlights Strategy for growth 150 Stable demand for Mysimba® continued
Slide 9: Hospital
Hospital Continued growth across the portfolio The Hospital segment comprises Navamedic’s antibiotics portfolio and medical nutrition products for the treatment of Inborn Errors of Metabolism (IEM) Q2 2024 revenue 28.9 MNOK (Q2 2023: 25.8 MNOK) Q2 highlights Strategy for growth The Antibiotics portf
Slide 10: Consumer Health
Consumer Health Broad product portfolio with stable growth The Consumer Health segment comprises Navamedic’s over-the-counter products, available to patients without a prescription Q2 2024 revenue 34.6 MNOK (Q2 2023: 31.3 MNOK) Q2 highlights Strategy for growth Eroxon launched in Sweden in May, beco
Slide 11: Delivering on our strategy for becoming a NOK 1 billion revenue company
Delivering on our strategy for becoming a NOK 1 billion revenue company GROWTH BASED ON A STRONG FOUNDATION 1 Untapping the potential within existing products, categories and territories. Strengthening the core with a disciplined approach to portfolio management, including adding attractive new prod
Slide 12: Financials
FINANCIALS @ Navamedic
Slide 13: Key consolidated profit and loss figures
Financials In Q2 2024, revenues were 26.2% higher than last year, including milestone revenues from the Orion Key consolidated profit and loss figures agreement. Without this, revenues were 7.8% higher than last year (in NOK '1000) Q2 2024 Q2 2023 YTD 2024 YTD 2023 FY 2023 Gross Profit came in at 46
Slide 14: Assets
Financials Assets (in NOK '1000) 30.06.2024 30.06.2023 31.12.2023 Inventory has decreased since Q1 and Goodwill 155 347 142 839 156 729 is anticipated to decrease further Deferred tax assets 930 835 930 throughout the year Other intangible assets 92 316 83 732 97 627 Trade receivables was higher due
Slide 15: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 30.06.24 30.06.23 31.12.2023 Total equity 244 102 211 444 222 391 Non-current interest-bearing borrowings 87 078 103 647 95 479 Non-current license liabilities 4 105 3 781 3 988 Non-current right of use liabilities 2 914 4 676 3 892 Equity ratio of 45
Slide 16: Cash flow Group – total operations
Financials Cash flow Group – total operations The cash flow from Operating Activities (in NOK '1000) Q2 2024 Q2 2023 Year 2023 is mainly the result of Net profit Net cash flow from operating activities 11 104 - 987 2 179 coupled with changes in working Net cash flow from investing activities - 187 -
Slide 17: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 18: Navamedic ASA summary and outlook
Navamedic ASA summary and outlook All business areas and new partnership support continued growth • Navamedic delivered NOK 156.3 million in revenue in Q2 2024, representing a Ambition of building a NOK 26.2% increase year-over-year one billion revenue company • The growth in Q2 is supported by grow
Slide 19: Q&A
Q&A 19 @ Navamedic
Slide 20: Want to know more?
Want to know more? Visit our website https://navamedic.com/ Follow us on LinkedIn #InvestInNavamedic Email infono@navamedic.com
Slide 21: Thank you for your attention!
Thank you for your attention! Navamedic’s Q3 2024 presentation will be held on 31 October 2024 21
Slide 22: Appendix
APPENDIX @ Navamedic
Slide 23: Basis for preparation and Definitions of Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 24: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any